These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32457416)

  • 1. Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis.
    Ou LC; Zhong S; Ou JS; Tian JW
    Acta Pharmacol Sin; 2021 Jan; 42(1):10-17. PubMed ID: 32457416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis.
    Pang AS; Dinesh T; Pang NY; Dinesh V; Pang KY; Yong CL; Lee SJJ; Yip GW; Bay BH; Srinivasan DK
    Molecules; 2024 Jun; 29(12):. PubMed ID: 38930939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The choice of targets and ligands for site-specific delivery of nanomedicine to atherosclerosis.
    Zia A; Wu Y; Nguyen T; Wang X; Peter K; Ta HT
    Cardiovasc Res; 2020 Nov; 116(13):2055-2068. PubMed ID: 32077918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research progress on the therapeutic effects of nanoparticles loaded with drugs against atherosclerosis.
    Shi T; Liu K; Peng Y; Dai W; Du D; Li X; Liu T; Song N; Meng Y
    Cardiovasc Drugs Ther; 2024 Oct; 38(5):977-997. PubMed ID: 37178241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
    Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.
    Chen W; Schilperoort M; Cao Y; Shi J; Tabas I; Tao W
    Nat Rev Cardiol; 2022 Apr; 19(4):228-249. PubMed ID: 34759324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy.
    Li Y; Feng Q; Wang L; Gao X; Xi Y; Ye L; Ji J; Yang X; Zhai G
    J Drug Target; 2024 Dec; 32(2):128-147. PubMed ID: 38217526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis.
    Perrotta P; Emini Veseli B; Van der Veken B; Roth L; Martinet W; De Meyer GRY
    Vascul Pharmacol; 2019 Jan; 112():72-78. PubMed ID: 29933080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies to deplete macrophages in atherosclerotic plaques.
    De Meyer I; Martinet W; De Meyer GR
    Br J Clin Pharmacol; 2012 Aug; 74(2):246-63. PubMed ID: 22309283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis in the atherosclerotic plaque.
    Camaré C; Pucelle M; Nègre-Salvayre A; Salvayre R
    Redox Biol; 2017 Aug; 12():18-34. PubMed ID: 28212521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological interventions for intraplaque neovascularization in atherosclerosis.
    Ugusman A; Hisam NSN; Othman NS; Anuar NNM; Hamid AA; Kumar J; Razmi MM; Aminuddin A
    Pharmacol Ther; 2024 Sep; 261():108685. PubMed ID: 38977083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration.
    van der Valk FM; van Wijk DF; Lobatto ME; Verberne HJ; Storm G; Willems MC; Legemate DA; Nederveen AJ; Calcagno C; Mani V; Ramachandran S; Paridaans MP; Otten MJ; Dallinga-Thie GM; Fayad ZA; Nieuwdorp M; Schulte DM; Metselaar JM; Mulder WJ; Stroes ES
    Nanomedicine; 2015 Jul; 11(5):1039-46. PubMed ID: 25791806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
    Bertrand MJ; Tardif JC
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
    Nelson JR; Wani O; May HT; Budoff M
    Vascul Pharmacol; 2017 Apr; 91():1-9. PubMed ID: 28263852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances of nanomedicine in treatment of atherosclerosis and thrombosis.
    Mao Y; Ren J; Yang L
    Environ Res; 2023 Dec; 238(Pt 2):116637. PubMed ID: 37482129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment.
    Zhang X; Centurion F; Misra A; Patel S; Gu Z
    Adv Drug Deliv Rev; 2023 Mar; 194():114709. PubMed ID: 36690300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
    Borow KM; Nelson JR; Mason RP
    Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound Microbubble Delivery Targeting Intraplaque Neovascularization Inhibits Atherosclerotic Plaque in an APOE-deficient Mouse Model.
    Yuan H; Hu H; Sun J; Shi M; Yu H; Li C; Sun YU; Yang Z; Hoffman RM
    In Vivo; 2018; 32(5):1025-1032. PubMed ID: 30150423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in imaging angiogenesis and inflammation in atherosclerosis.
    Zagorchev L; Mulligan-Kehoe MJ
    Thromb Haemost; 2011 May; 105(5):820-7. PubMed ID: 21331441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Microenvironment of Vulnerable Atherosclerotic Plaques: An Emerging Diagnosis and Therapy Strategy for Atherosclerosis.
    Zhang S; Liu Y; Cao Y; Zhang S; Sun J; Wang Y; Song S; Zhang H
    Adv Mater; 2022 Jul; 34(29):e2110660. PubMed ID: 35238081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.